NCT02349386 - Maintaining Suppression of Testosterone With Transdermal Estradiol Gel | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

June 14, 2017

Study Completion Date

January 10, 2018

Conditions

Cancer of the Prostate

Interventions

DRUG

BHR-200 (0.36% transdermal 17β-estradiol gel)

An absorptive hydroalcoholic gel preparation containing 17β-estradiol.

DRUG

Placebo

An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.

Trial Locations (12)

Associated Medical Professionals of NY (AMP of NY), Syracuse

Urologic Consultants of Southeastern Pennsylvania (UCSEPA), Bala-Cynwyd

Eastern Urological Associates, Greenville

Carolina Urologic Research Center, Myrtle Beach

Advanced Urology Institute, Daytona Beach

South Florida Medical Research, Aventura

Adult Pediatric Urology, PC, Council Bluffs

Adult Pediatric Urology, PC, Omaha

Urology Clinics of North Texas, Dallas

Urological Associates of Southern Arizona, Tucson

AccumetRX Clinical Trials, Albuquerque

Delaware Valley Urology, Voorhees Township